← Oncology Approval Tracker

FDA DECISION ·

Monjuvi + lenalidomide

tafasitamab-cxix + lenalidomide · MorphoSys US

Accelerated approvalNew therapyDiffuse large B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including disease arising from low-grade lymphoma, who were ineligible for autologous stem cell transplant.

LAMPGEN ANALYSIS

Why it matters

Added a CD19-directed antibody plus lenalidomide for transplant-ineligible patients under accelerated approval.

What research teams should watch

Document transplant ineligibility and coordinate oral lenalidomide controls with infusion and blood-count monitoring.

PRIMARY RECORDS

Sources